Loading...
XNAS
ANGO
Market cap552mUSD
Dec 05, Last price  
13.47USD
1D
-1.10%
1Q
25.54%
Jan 2017
-20.15%
IPO
-5.01%
Name

AngioDynamics Inc

Chart & Performance

D1W1MN
XNAS:ANGO chart
P/E
P/S
1.89
EPS
Div Yield, %
Shrs. gr., 5y
1.54%
Rev. gr., 5y
2.06%
Revenues
292m
-3.76%
78,451,000112,227,000166,500,000195,054,000216,035,000215,957,000221,787,000342,026,000354,455,000356,974,000353,690,000349,643,000344,285,000359,484,000264,157,000291,010,000316,219,000338,752,000303,914,000292,498,000
Net income
-34m
L-81.56%
6,866,000-9,127,00010,889,0009,932,00012,312,0008,226,000-5,094,000-614,0003,088,000-3,268,000-44,451,0007,008,00016,335,00061,340,000-165,787,000-31,548,000-26,547,000-52,442,000-184,349,000-33,993,000
CFO
-11m
L-61.62%
3,219,0008,784,00025,907,00019,942,00039,959,00033,870,00010,829,00026,294,00025,284,00026,242,00045,216,00055,745,00041,287,00037,440,000-14,554,00024,093,000-7,194,00078,000-28,158,000-10,808,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
IPO date
May 27, 2004
Employees
815
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑052024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑052016‑05
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT